EGFR and non-small cell lung carcinoma: In this regard, recent data have demonstrated that a potent TKI of EGFR, erlotinib, in combination with the glutaminase inhibitor CB-839 severely affects metabolic and energetic balances, leading to apoptotic death of NSCLC cancer cells [49].